相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
Morgan E. Rook et al.
BIODRUGS (2022)
Recent developments in the management of Huntington's disease
Shanaika J. Devadiga et al.
BIOORGANIC CHEMISTRY (2022)
A Review On Huntington Protein: Insight Into Protein Aggregation and Therapeutic Interventions
Ekambaram Srinivasan et al.
CURRENT DRUG METABOLISM (2022)
Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases
Wei Liu et al.
DRUG DISCOVERY TODAY (2022)
Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases
Yumeng Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases
Anja Holm et al.
RNA BIOLOGY (2022)
Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease
Subrata Pradhan et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2022)
Huntington's Disease Clinical Trials Corner: April 2022
Carlos Estevez-Fraga et al.
JOURNAL OF HUNTINGTONS DISEASE (2022)
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2022)
Current and Possible Future Therapeutic Options for Huntington's Disease
Mackenzie W. Ferguson et al.
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2022)
Protective Effect of Natural Products against Huntington's Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action
Pei Teng Lum et al.
ACS CHEMICAL NEUROSCIENCE (2021)
Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex
Xiao-jing Li et al.
ACTA PHARMACOLOGICA SINICA (2021)
Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease
Hidetoshi Komatsu
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Huntington's Disease: New Frontiers in Therapeutics
Ling Pan et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2021)
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class Ila HDAC Inhibitors for Huntington's Disease
Andrew J. Stott et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington's Disease Mice
Katharina Hecklau et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2021)
Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules
Hidetoshi Komatsu
FRONTIERS IN CELLULAR NEUROSCIENCE (2021)
Small molecule splicing modifiers with systemic HTT-lowering activity
Anuradha Bhattacharyya et al.
NATURE COMMUNICATIONS (2021)
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's Disease
Amanda Van de Poel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
Filipe B. Rodrigues et al.
JOURNAL OF NEUROCHEMISTRY (2021)
A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity
Houda G. Khaled et al.
SCIENTIFIC REPORTS (2021)
Emerging therapeutics in Huntington's disease
Robert Wiggins et al.
EXPERT OPINION ON EMERGING DRUGS (2021)
New Avenues for the Treatment of Huntington's Disease
Amy Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington's disease
Priya Sharma et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2021)
Transglutaminase 2 as a therapeutic target for neurological conditions
Jeffrey W. Keillor et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes
Congcong Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
A selectivity study of polysubstituted pyridinylimidazoles as dual inhibitors of JNK3 and p38α MAPK based on 3D-QSAR, molecular docking, and molecular dynamics simulation
Le Fu et al.
STRUCTURAL CHEMISTRY (2021)
Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases
Amanda K. Davis et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors
Yan-Fa Yu et al.
ACS CHEMICAL NEUROSCIENCE (2020)
Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present)
Agnieszka Zagorska
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Structural basis of ligand recognition and self-activation of orphan GPR52
Xi Lin et al.
NATURE (2020)
A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo
Masayuki Nakamori et al.
NATURE GENETICS (2020)
Synthesis and Selective Functionalization of Thiadiazine 1,1-Dioxides with Efficacy in a Model of Huntington's Disease
Leila Terrab et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction
Jesus M. Ontoria et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Medical, Surgical, and Genetic Treatment of Huntington Disease
Christine M. Stahl et al.
NEUROLOGIC CLINICS (2020)
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Sarah J. Tabrizi et al.
NATURE REVIEWS NEUROLOGY (2020)
Targeted Proteomics Combined with Affinity Mass Spectrometry Analysis Reveals Antagonist E7 Acts As an Intracellular Covalent Ligand of Orphan Receptor GPR52
Mengna Ma et al.
ACS CHEMICAL BIOLOGY (2020)
Huntington's Disease Clinical Trials Corner: April 2020
Filipe B. Rodrigues et al.
JOURNAL OF HUNTINGTONS DISEASE (2020)
A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia
Thomas A. Macek et al.
SCHIZOPHRENIA RESEARCH (2019)
Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors
Minhee Jang et al.
BRAIN BEHAVIOR AND IMMUNITY (2019)
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models
Leticia Toledo-Sherman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Discovery of Arginine Ethyl Ester as Polyglutamine Aggregation Inhibitor: Conformational Transitioning of Huntingtin N-Terminus Augments Aggregation Suppression
Virender Singh et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs)
Eshan Khan et al.
BIOCHIMIE (2019)
Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
Daniel A. Ryskamp et al.
FRONTIERS IN NEUROSCIENCE (2019)
Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds
Zhaoyang Li et al.
NATURE (2019)
Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington's disease
Ferah Yildirim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
SQSTM1/p62: A Potential Target for Neurodegenerative Disease
Shifan Ma et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein
Eshan Khan et al.
SCIENTIFIC REPORTS (2019)
Synthesis and evaluation of esterified Hsp70 agonists in cellular models of protein aggregation and folding
Annette N. Chiang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class Ha histone deacetylase inhibitor
Christopher A. Luckhurst et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats
Ravi Chandra Sekhara Reddy Danduga et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes
Haikun Song et al.
BRAIN (2018)
Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease
Edith L. Pfister et al.
HUMAN GENE THERAPY (2018)
Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease
Xiao Zhou et al.
HUMAN MOLECULAR GENETICS (2018)
GENE EDITING To cut is to cure
Michael Eisenstein
NATURE (2018)
Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease
Marissa Dean et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease
Anne Ast et al.
MOLECULAR CELL (2018)
Therapeutic approaches to Huntington disease: from the bench to the clinic
Nicholas S. Caron et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY AND SAFETY STUDY OF THE PDE10A INHIBITOR PF-02545920 IN HUNTINGTON DISEASE (AMARYLLIS)
Marielle Delnomdedieu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3
Francesco Ansideri et al.
ACS OMEGA (2018)
Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs)
Eshan Khan et al.
ACS CHEMICAL BIOLOGY (2018)
Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease
Jun Wu et al.
JOURNAL OF HUNTINGTONS DISEASE (2018)
Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors
Minsoo Song et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
DNA REPAIR A unifying mechanism in neurodegeneration
Christopher A. Ross et al.
NATURE (2017)
7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway
Gerardo Garcia-Diaz Barriga et al.
HUMAN MOLECULAR GENETICS (2017)
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3
Felix Muth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders
Sidharth Mehan et al.
NEURAL REGENERATION RESEARCH (2017)
Conformational dynamics and self-association of intrinsically disordered Huntingtin exon 1 in cells
Steffen Buening et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2017)
RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA
Sebastian Aguiar et al.
TRANSLATIONAL NEURODEGENERATION (2017)
2-Alkylsulfanyl-4(5)-aryl-5(4)-heteroarylimidazoles: An Overview on Synthetic Strategies and Biological Activity
Pierre Koch et al.
ARCHIV DER PHARMAZIE (2017)
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Marta Garcia-Miralles et al.
JCI INSIGHT (2017)
Effect of Praeruptorin C on 3-nitropropionic acid induced Huntington's disease-like symptoms in mice
Lu Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Sulforaphane Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity by Activating the Keap1-Nrf2-ARE Pathway and Inhibiting the MAPKs and NF-κB Pathways
Minhee Jang et al.
MOLECULAR NEUROBIOLOGY (2016)
Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class Ila Histone Deacetylase (HDAC) Inhibitors
Christopher A. Luckhurst et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase
Francesco Ansideri et al.
ANALYTICAL BIOCHEMISTRY (2016)
Effect of embelin against 3-nitropropionic acid-induced Huntington's disease in rats
Shivsharan B. Dhadde et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!
Sk. Abdul Amin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Protective effect of naringin on 3-nitropropionic acid-induced neurodegeneration through the modulation of matrix metalloproteinases and glial fibrillary acidic protein
Kulasekaran Gopinath et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2016)
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease
Vahri Beaumont et al.
EXPERIMENTAL NEUROLOGY (2016)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease A Randomized Clinical Trial
Samuel Frank et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions
Zheng-Yu Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Dihydromyricetin Ameliorates 3NP-induced Behavioral Deficits and Striatal Injury in Rats
Shuhua Mu et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2016)
Functional Indicators of Glutamate Transport in Single Striatal Astrocytes and the Influence of Kir4.1 in Normal and Huntington Mice
Anton Dvorzhak et al.
JOURNAL OF NEUROSCIENCE (2016)
Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model
Jun Wu et al.
JOURNAL OF NEUROSCIENCE (2016)
Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice
Ruotian Jiang et al.
JOURNAL OF NEUROSCIENCE (2016)
Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: Possible role of oxidative stress, neuroinflammation, and neurotransmitters
Sumit Jamwal et al.
PHYSIOLOGY & BEHAVIOR (2016)
α-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane
Elodie Monsellier et al.
SCIENTIFIC REPORTS (2016)
Structure-based Inhibitor Design for the Intrinsically Disordered Protein c-Myc
Chen Yu et al.
SCIENTIFIC REPORTS (2016)
SIRT2-and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models
Luisa Quinti et al.
CELL CHEMICAL BIOLOGY (2016)
Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease
Yan Gao et al.
ACTA PHARMACOLOGICA SINICA (2015)
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
Ferdinando Squitieri et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Lead Optimization toward Proof-of-Concept Tools for Huntington's Disease within a 4-(1H-Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors
John Wityak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Neferine Attenuates the Protein Level and Toxicity of Mutant Huntingtin in PC-12 Cells via Induction of Autophagy
Vincent Kam Wai Wong et al.
MOLECULES (2015)
Transcellular spreading of huntingtin aggregates in the Drosophila brain
Daniel T. Babcock et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective
Anna Kaplan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Structural Elucidation of a Small Molecule Inhibitor of Protein Disulfide Isomerase
Anna Kaplan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors
Mohammad A. Khanfar et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain
Margaret M. P. Pearce et al.
NATURE COMMUNICATIONS (2015)
A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity
Yuwei Yao et al.
ELIFE (2015)
Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases
Felix Muth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Genistein Improves 3-NPA-Induced Memory Impairment in Ovariectomized Rats: Impact of Its Antioxidant, Anti-Inflammatory and Acetylcholinesterase Modulatory Properties
Esther T. Menze et al.
PLOS ONE (2015)
Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model
Wenxiao Jiang et al.
PLOS ONE (2015)
Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012
Jose-Manuel Bartolome-Nebreda et al.
PHARMACEUTICAL PATENT ANALYST (2015)
The anti-apoptotic and anti-inflammatory properties of puerarin attenuate 3-nitropropionic-acid induced neurotoxicity in rats
Heba M. Mahdy et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2014)
Recent Progress in the Design, Study, and Development of c-Jun N-Terminal Kinase Inhibitors as Anticancer Agents
Abdellah Messoussi et al.
CHEMISTRY & BIOLOGY (2014)
Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3-Nitropropionic Acid-Induced Rat Model of Huntington's Disease
Joy Chakraborty et al.
CNS NEUROSCIENCE & THERAPEUTICS (2014)
Development and characterization of 3-(benzylsulfonamido) benzamides as potent and selective SIRT2 inhibitors
Mohammad A. Khanfar et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
Neuroprotective activity of L-theanine on 3-nitropropionic acid-induced neurotoxicity in rat striatum
Sumathi Thangarajan et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2014)
Discovery of Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis
Zheng-Yu Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of 142-Fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a Highly Potent, Selective, and Orally Active Phosphodiesterase 10A (PDE10A) Inhibitor
Jun Kunitomo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease
Yanying Liu et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease
Nan Wang et al.
NATURE MEDICINE (2014)
Anatomical Transcriptome of G Protein-Coupled Receptors Leads to the Identification of a Novel Therapeutic Candidate GPR52 for Psychiatric Disorders
Hidetoshi Komatsu et al.
PLOS ONE (2014)
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte et al.
PLOS ONE (2014)
Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease
Xiao-Hong Lu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Edward Seto et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin
Panchanan Maiti et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Skeletal muscle pathology in Huntington's disease
Daniel Zielonka et al.
FRONTIERS IN PHYSIOLOGY (2014)
Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction
Longqin Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Phosphodiesterase 10A inhibitors: a 2009-2012 patent update
Jan Kehler
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntingtons disease
Mali Jiang et al.
HUMAN MOLECULAR GENETICS (2013)
Onjisaponin B Derived from Radix Polygalae Enhances Autophagy and Accelerates the Degradation of Mutant α-Synuclein and Huntingtin in PC-12 Cells
An-Guo Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes
Maddalena Costanzo et al.
JOURNAL OF CELL SCIENCE (2013)
Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease
Roland W. Buerli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Neuroprotective Effect of Lutein Against 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms: Possible Behavioral, Biochemical, and Cellular Alterations
Yogita Binawade et al.
JOURNAL OF MEDICINAL FOOD (2013)
MAP Kinase Phosphatase 1 (MKP-1/DUSP1) Is Neuroprotective in Huntington's Disease via Additive Effects of JNK and p38 Inhibition
David M. Taylor et al.
JOURNAL OF NEUROSCIENCE (2013)
A Small Molecule TrkB Ligand Reduces Motor Impairment and Neuropathology in R6/2 and BACHD Mouse Models of Huntington's Disease
Danielle A. Simmons et al.
JOURNAL OF NEUROSCIENCE (2013)
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Kirupa Sathasivam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Preparation and evaluation of BBB-permeable trehalose derivatives as potential therapeutic agents for Huntington's disease
Jungkyun Im et al.
MEDCHEMCOMM (2013)
Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway
A. Hyrskyluoto et al.
CELL DEATH & DISEASE (2013)
Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity
Salvatore La Rosa et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration
Michal Mielcarek et al.
PLOS BIOLOGY (2013)
Fibrillar α-Synuclein and Huntingtin Exon 1 Assemblies Are Toxic to the Cells
Laura Pieri et al.
BIOPHYSICAL JOURNAL (2012)
Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated Phenotypes
CELL STEM CELL (2012)
Mitochondrial DNA damage Is associated with reduced mitochondrial bioenergetics in Huntington's disease
Almas Siddiqui et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntingtons disease mice: implications for the ubiquitinproteasomal and autophagy systems
Haiqun Jia et al.
HUMAN MOLECULAR GENETICS (2012)
A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client Protein
Barbara Baldo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Identification of Novel Potentially Toxic Oligomers Formed in Vitro from Mammalian-derived Expanded huntingtin Exon-1 Protein
Leslie G. Nucifora et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
trans-(-)-ε-Viniferin Increases Mitochondrial Sirtuin 3 (SIRT3), Activates AMP-activated Protein Kinase (AMPK), and Protects Cells in Models of Huntington Disease
Jinrong Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors
Takayoshi Suzuki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery and Structure-Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington's Disease
Michael E. Prime et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2012)
The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2012)
Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway
Valentina Castiglioni et al.
NEUROBIOLOGY OF DISEASE (2012)
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease
Haiqun Jia et al.
NEUROBIOLOGY OF DISEASE (2012)
JNK3 Perpetuates Metabolic Stress Induced by Aβ Peptides
Sung Ok Yoon et al.
NEURON (2012)
Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease
Lara Moumne et al.
PLOS ONE (2012)
SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo
Anna Bobrowska et al.
PLOS ONE (2012)
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease
Michael E. Prime et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease
John Wityak et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington's Disease Mouse Models
Vanita Chopra et al.
CELL REPORTS (2012)
Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048
Maria G. Beconi et al.
DRUG METABOLISM AND DISPOSITION (2012)
A Brain-Permeable Small Molecule Reduces Neuronal Cholesterol by Inhibiting Activity of Sirtuin 2 Deacetylase
David M. Taylor et al.
ACS CHEMICAL BIOLOGY (2011)
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Daniel Zwilling et al.
CELL (2011)
Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment
Jun Wu et al.
CHEMISTRY & BIOLOGY (2011)
The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease
Susanna Campesan et al.
CURRENT BIOLOGY (2011)
A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3
Marcia Goettert et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2011)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
Role of Inositol 1,4,5-Trishosphate Receptors in Pathogenesis of Huntington's Disease and Spinocerebellar Ataxias
Ilya Bezprozvanny
NEUROCHEMICAL RESEARCH (2011)
PATHOPHYSIOLOGY OF HUNTINGTON'S DISEASE: TIME-DEPENDENT ALTERATIONS IN SYNAPTIC AND RECEPTOR FUNCTION
L. A. Raymond et al.
NEUROSCIENCE (2011)
A New Drug Design Targeting the Adenosinergic System for Huntington's Disease
Nai-Kuei Huang et al.
PLOS ONE (2011)
SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease
Michal Mielcarek et al.
PLOS ONE (2011)
N1-Benzyl substituted cambinol analogues as isozyme selective inhibitors of the sirtuin family of protein deacetylases
Federico Medda et al.
MEDCHEMCOMM (2011)
Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity
Marcia Goettert et al.
ANALYTICAL BIOCHEMISTRY (2010)
Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat
Keith T. Gagnon et al.
BIOCHEMISTRY (2010)
Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in Vivo
Justin Legleiter et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Mutant huntingtin impairs Ku70-mediated DNA repair
Yasushi Enokido et al.
JOURNAL OF CELL BIOLOGY (2010)
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Stephen M. Massa et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Small Molecule JNK (c-Jun N-Terminal Kinase) Inhibitors
M. Arshad Siddiqui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine
Diana Elinos-Calderon et al.
JOURNAL OF NEURAL TRANSMISSION (2010)
Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease
Korrapati V. Sathyasaikumar et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins
Benjamin G. Hoffstrom et al.
NATURE CHEMICAL BIOLOGY (2010)
Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system
Rajat Sandhir et al.
NEUROCHEMISTRY INTERNATIONAL (2010)
Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice
Austen J. Milnerwood et al.
NEURON (2010)
A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model
Andrey S. Tsvetkov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis
Ruth Luthi-Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors
Takayoshi Suzuki et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Small molecule drug discovery for Huntington's Disease
Wolfgang Fecke et al.
DRUG DISCOVERY TODAY (2009)
ROS scavenging capacity and neuroprotective effect of α-mangostin against 3-nitropropionic acid in cerebellar granule neurons
Jose Pedraza-Chaverri et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2009)
Sesamol attenuate 3-nitropropionic acid-induced Huntington-like behavioral, biochemical, and cellular alterations in rats
Puneet Kumar et al.
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH (2009)
Novel Cambinol Analogs as Sirtuin Inhibitors: Synthesis, Biological Evaluation, and Rationalization of Activity
Federico Medda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Beyond the brain: widespread pathology in Huntington's disease
Jorien M. M. van der Burg et al.
LANCET NEUROLOGY (2009)
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs
Jiaxin Hu et al.
NATURE BIOTECHNOLOGY (2009)
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin
Shu-ichi Okamoto et al.
NATURE MEDICINE (2009)
Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin
Gerardo A. Morfini et al.
NATURE NEUROSCIENCE (2009)
Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice
Mei Li et al.
NEUROBIOLOGY OF DISEASE (2009)
Calcium signaling and neurodegenerative diseases
Ilya Bezprozvanny
TRENDS IN MOLECULAR MEDICINE (2009)
High throughput screening for neurodegeneration and complex disease phenotypes
Hemant Varma et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2008)
Mechanisms of neurodegeneration in Huntington's disease
Joana M. Gil et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease
Chuan-En Wang et al.
HUMAN MOLECULAR GENETICS (2008)
Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease
Judit Pallos et al.
HUMAN MOLECULAR GENETICS (2008)
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
Jodi L. McBride et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice
Elizabeth A. Thomas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Sigma-1 receptor chaperones at the ER-Mitochondrion interface regulate Ca2+ signaling and cell survival
Teruo Hayashi et al.
CELL (2007)
Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages
R. Andres Floto et al.
AUTOPHAGY (2007)
A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse
Vanita Chopra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease
Tiago Fleming Outeiro et al.
SCIENCE (2007)
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models
Sovan Sarkar et al.
NATURE CHEMICAL BIOLOGY (2007)
Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models
Ghazaleh Sadri-Vakili et al.
HUMAN MOLECULAR GENETICS (2007)
Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments
Myra Coufal et al.
JOURNAL OF BIOMOLECULAR SCREENING (2007)
Selective inhibitors of death in mutant huntingtin cells
Hemant Varma et al.
NATURE CHEMICAL BIOLOGY (2007)
Role of brain-derived neurotrophic factor in Huntington's disease
Chiara Zuccato et al.
PROGRESS IN NEUROBIOLOGY (2007)
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease
Hoon Ryu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
2-anilinobenzamides as SIRT inhibitors
Takayoshi Suzuki et al.
CHEMMEDCHEM (2006)
Juvenile Huntington disease
Nimeshan Geevasinga et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2006)
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Paolo Guidetti et al.
NEUROBIOLOGY OF DISEASE (2006)
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase
M Borrell-Pagès et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons
DTW Chang et al.
NEUROBIOLOGY OF DISEASE (2006)
Tetrabenazine as antichorea therapy in Huntington disease - A randomized controlled trial
FJ Marshall et al.
NEUROLOGY (2006)
Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers
G Hoffner et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats
M Tariq et al.
BRAIN RESEARCH BULLETIN (2005)
Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions
EJ Slow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity
C Cleren et al.
JOURNAL OF NEUROCHEMISTRY (2005)
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease
F Giorgini et al.
NATURE GENETICS (2005)
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo
XQ Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Huntingtin-protein interactions and the pathogenesis of Huntington's disease|
SH Li et al.
TRENDS IN GENETICS (2004)
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
M Tanaka et al.
NATURE MEDICINE (2004)
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro
E Trushina et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules
LR Gauthier et al.
CELL (2004)
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
P Guidetti et al.
NEUROBIOLOGY OF DISEASE (2004)
Mapping global histone acetylation patterns to gene expression
SK Kurdistani et al.
CELL (2004)
Targeting JNK3 for the treatment of neurodegenerative disorders
L Resnick et al.
DRUG DISCOVERY TODAY (2004)
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
B Ravikumar et al.
NATURE GENETICS (2004)
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
M Arrasate et al.
NATURE (2004)
Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study
YP Deng et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2004)
A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor
SK Pollitt et al.
NEURON (2003)
DNA damage induced by polyglutamine-expanded proteins
P Giuliano et al.
HUMAN MOLECULAR GENETICS (2003)
Mechanisms of transcriptional dysregulation in Huntington's disease
R Luthi-Carter et al.
CLINICAL NEUROSCIENCE RESEARCH (2003)
Huntingtin and Huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1
TS Tang et al.
NEURON (2003)
Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay
V Heiser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells
W Yang et al.
HUMAN MOLECULAR GENETICS (2002)
'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease
P Mastroberardino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain
R Luthi-Carter et al.
HUMAN MOLECULAR GENETICS (2002)
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
C Zuccato et al.
SCIENCE (2001)
Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase 1 gene
S Dhakshinamoorthy et al.
ONCOGENE (2001)
Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease
A Sittler et al.
HUMAN MOLECULAR GENETICS (2001)
Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells
WJ Chun et al.
NEUROBIOLOGY OF DISEASE (2001)
Juvenile onset Huntington's disease - Clinical and research perspectives
MA Nance et al.
MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS (2001)
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
A Yamamoto et al.
CELL (2000)
分享论文
